A possible fifth case of a rare and deadly brain infection linked to the multiple sclerosis (MS) drug Tysabri has been reported to federal regulators, The Wall Street Journal reported today.
The case was reported May 16 through the FDA’s Adverse Event Reporting System, which collects reports of possible drug reactions from doctors and drug makers.
An FDA spokeswoman told the newspaper that these reports don’t represent confirmed cases.
The fifth possible case was reported by an unnamed health professional and concerns a female patient whose age is undisclosed. No other details of her condition were available, the newspaper report said.